

Acute Leukemia FORUM 2010

Advances and Controversies in the Biology and Therapy of
Acute Leukemia and Myelodysplasia
Friday, April 9, 2010 – San Francisco, CA

7:00–7:40 Registration and Breakfast
7:45–7:50 Introduction
Jacob M. Rowe, Co-Chairman

11:25–11:35 Discussion
11:35–12:35 Lunch

Session 1: Basic Biology

Moderators: Marshall A. Lichtman, MD
Kenneth Kaushansky, MD

7:50–8:05 Genetic deletions in AML and MDS
Benjamin L. Ebert, MD

8:05–8:15 Discussion

8:15–8:30 Epigenetics in AML
Ari M. Melnick, MD

8:30–8:40 Discussion

8:40–8:55 MicroRNA and prognosis in AML
Alan D. D'Andrea, MD

8:55–9:05 Discussion

9:05–9:25 Break

Session 3: Bone Marrow Transplantation

Moderators: Armand Keating, MD
Mary M. Horowitz, MD

12:40–12:55 Are we close to recommending reduced-intensity conditioning for all allogeneic transplants in CR1?
Frederick R. Appelbaum, MD

12:55–1:05 Discussion

1:05–1:20 Can every patient be mobilized?
John F. DiPersio, MD, PhD

1:20–1:30 Discussion

1:30–1:45 How closely related is graft-versus-leukemia to donor/recipient disparity?
Daniel J. Weisdorf, MD

1:45–1:55 Discussion

1:55–2:10 Have we made progress in the management of chronic graft-versus-host-disease?
Stephanie J. Lee, MD

2:10–2:20 Discussion

2:20–2:40 Break

Session 2: Induction and Post-Remission Therapy

Moderators: Elihu H. Estey, MD
Charles A. Schiffer, MD

9:30–9:45 New agents in post-remission therapy
Richard M. Stone, MD

9:45–9:55 Discussion

9:55–10:10 Are we nearer to curing patients with MDS?
Mikael A. Sekeres, MD, MS

10:10–10:20 Discussion

10:20–10:35 Will new tyrosine kinase inhibitors make an impact on AML?
Mark J. Levis, MD, PhD

10:35–10:45 Discussion

10:45–11:00 Is there any progress in the treatment of older adults beyond conventional therapy?
Harry Paul Erba, MD, PhD

11:00–11:10 Discussion

11:10–11:25 Is there a role for differentiating therapy in non-APL AML?
H. Phillip Koeffler, MD

Session 4: Supportive Care and Perspective

Moderators: Emil J. Freireich, MD, D.Sc. (Hon.)
Beverly S. Mitchell, MD

2:45–3:00 Management of platelet refractoriness
Sherrill J. Slichter, MD

3:00–3:10 Discussion

Keynote Address

3:10–3:20 Introduction of Neal S. Young, MD
Jaroslaw P. Maciejewski, MD, PhD

3:20–3:50 Ernest Beutler Memorial Lecture
Telomere biology and cancer
Neal S. Young, MD

3:50–3:55 Discussion

3:55–4:00 Concluding Remarks and Close
Martin S. Tallman, MD, Co-Chairman